Akebia Therapeutics (AKBA) Amortizatization of Intangibles (2014 - 2021)
Akebia Therapeutics (AKBA) posted quarterly Amortizatization of Intangibles of $4000.0 for Q2 2021, up 100.0% year-over-year from $2000.0 in Q2 2020, and down 63.64% quarter-over-quarter from $11000.0 in Q1 2021.
Akebia Therapeutics (AKBA) Amortizatization of Intangibles (2014 - 2021) Analysis & Trends
Akebia Therapeutics (AKBA) has reported Amortizatization of Intangibles for 8 consecutive years, with $4000.0 the latest figure, recorded in Q2 2021.
- In Q2 2021, Amortizatization of Intangibles rose 100.0% year-over-year to $4000.0; the TTM figure through Mar 2022 stood at $4000.0 (down 93.1% YoY), while the FY2021 annual figure was $15000.0, down 68.09% from the prior year.
- Amortizatization of Intangibles fell to $4000.0 in Q2 2021 per AKBA's latest filing, from $11000.0 in the prior quarter.
- Across five years, Amortizatization of Intangibles topped out at $534000.0 in Q4 2018 and bottomed at -$198000.0 in Q2 2017.
- Historically, Amortizatization of Intangibles has averaged $88411.8 across 5 years, with a median of $24000.0 in 2019.
- Annual changes were most pronounced in 2018 — Amortizatization of Intangibles jumped 897.01% — and 2020, when it sank 99.04%.
- Akebia Therapeutics' Amortizatization of Intangibles stood at -$67000.0 in 2017, then surged by 897.01% to $534000.0 in 2018, then plunged by 95.51% to $24000.0 in 2019, then plunged by 33.33% to $16000.0 in 2020, then slumped by 75.0% to $4000.0 in 2021.
- Business Quant data shows AKBA's Amortizatization of Intangibles at $4000.0 in Q2 2021, $11000.0 in Q1 2021, and $16000.0 in Q4 2020.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Amortizatization of Intangibles (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.91 Bn | 42.95 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 43.15 Bn | 39.49 Bn | 2.15 Bn | - |
| 3 | Zoetis | 31.52 Bn | 29.84 Bn | 1.05 Bn | - |
| 4 | Takeda Pharmaceutical | 28.58 Bn | 22.78 Bn | 5.10 Bn | - |
| 5 | United Therapeutics | 22.16 Bn | 19.50 Bn | 683.80 Mn | - |
| 6 | Viatris | 18.76 Bn | 17.87 Bn | 1.46 Bn | - |
| 7 | Neurocrine Biosciences | 15.48 Bn | 15.09 Bn | 935.80 Mn | 900,000.00 |
| 8 | Elanco Animal Health | 11.69 Bn | 11.16 Bn | 798.00 Mn | - |
| 9 | Dr Reddys Laboratories | 10.13 Bn | 9.96 Bn | - | - |
| 10 | Akebia Therapeutics | 247.98 Mn | 92.43 Mn | 38.70 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2021 | 4,000.00 |
| Jun 30, 2021 | 4,000.00 |
| Mar 31, 2021 | 11,000.00 |
| Mar 31, 2021 | 11,000.00 |
| Dec 31, 2020 | 16,000.00 |
| Dec 31, 2020 | 16,000.00 |
| Sep 30, 2020 | 29,000.00 |
| Sep 30, 2020 | 29,000.00 |
| Jun 30, 2020 | 2,000.00 |
| Jun 30, 2020 | 2,000.00 |
| Dec 31, 2019 | 24,000.00 |
| Dec 31, 2019 | 24,000.00 |
| Sep 30, 2019 | 110,000.00 |
| Sep 30, 2019 | 110,000.00 |
| Jun 30, 2019 | 208,000.00 |
| Jun 30, 2019 | 208,000.00 |
| Mar 31, 2019 | 477,000.00 |
| Mar 31, 2019 | 477,000.00 |
| Dec 31, 2018 | 534,000.00 |
| Dec 31, 2018 | 534,000.00 |